Trial · NCT02531035
Adverse events104
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 104
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Diarrhoea | Gastrointestinal disorders | Placebo | 17 | 703 | 22 |
| other | Diarrhoea | Gastrointestinal disorders | Sotagliflozin 400 mg | 35 | 699 | 41 |
| other | Viral upper respiratory tract infection | Infections and infestations | Placebo | 55 | 703 | 62 |
| other | Viral upper respiratory tract infection | Infections and infestations | Sotagliflozin 400 mg | 41 | 699 | 46 |
| serious | Hypotension | Vascular disorders | Placebo | 0 | 703 | 0 |
| serious | Hypotension | Vascular disorders | Sotagliflozin 400 mg | 1 | 699 | 1 |
| serious | Peripheral arterial occlusive disease | Vascular disorders | Placebo | 1 | 703 | 1 |
| serious | Peripheral arterial occlusive disease | Vascular disorders | Sotagliflozin 400 mg | 0 | 699 | 0 |
| serious | Invasive ductal breast carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Placebo | 1 | 703 | 1 |
| serious | Invasive ductal breast carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Sotagliflozin 400 mg | 0 | 699 | 0 |
| serious | Lung neoplasm malignant | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Placebo | 1 | 703 | 1 |
| serious | Lung neoplasm malignant | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Sotagliflozin 400 mg | 0 | 699 | 0 |
| serious | Uterine leiomyoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Placebo | 0 | 703 | 0 |
| serious | Uterine leiomyoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Sotagliflozin 400 mg | 1 | 699 | 1 |
| serious | Chest pain | General disorders | Placebo | 1 | 703 | 1 |
| serious | Chest pain | General disorders | Sotagliflozin 400 mg | 0 | 699 | 0 |
| serious | Alcoholism | Psychiatric disorders | Placebo | 1 | 703 | 1 |
| serious | Alcoholism | Psychiatric disorders | Sotagliflozin 400 mg | 0 | 699 | 0 |
| serious | Anxiety | Psychiatric disorders | Placebo | 0 | 703 | 0 |
| serious | Anxiety | Psychiatric disorders | Sotagliflozin 400 mg | 1 | 699 | 1 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02531035/events